Mitigating time toxicity in lymphoma and multiple myeloma

Area of Science:

• Oncology
• Hematology
• Patient-centered care

Background:

• Time toxicity in oncology describes burdensome healthcare interactions affecting patient well-being.
• Frequent appointments and treatment schedules can significantly impact patients with hematologic malignancies.

Purpose of the Study:

• To review manifestations of time toxicity in non-Hodgkin lymphoma and multiple myeloma.
• To discuss the impact of time toxicity on clinical decision-making and treatment choices.
• To explore strategies for mitigating time toxicity in lymphoma and myeloma therapies.

Main Methods:

• Literature review examining time toxicity in non-Hodgkin lymphoma and multiple myeloma.
• Analysis of how time toxicity influences treatment selection (e.g., chemoimmunotherapy vs. targeted agents).
• Discussion of time toxicity in the context of novel therapies like CAR T-cell and bispecific antibodies.

Main Results:

• Time toxicity influences treatment choices, such as chemoimmunotherapy versus lenalidomide-rituximab in follicular lymphoma.
• Optimal dosing schedules for proteasome inhibitors and bisphosphonates in myeloma are informed by time toxicity.
• Chimeric antigen receptor T-cell therapies and bispecific antibodies exhibit distinct time toxicity profiles.

Conclusions:

• Time toxicity is a crucial factor in patient care for lymphoma and myeloma, impacting treatment decisions.
• Measuring time toxicity as a trial endpoint presents challenges but is vital for patient-centered care.
• Strategies exist to reduce the time toxicity of therapies without compromising efficacy or safety.